Latest guidelines for management of hypertension in pregnancy
Reading File
Finding Sources
Searching PubMed
"hypertension" AND "pregnancy" AND "guidelines"
Searching the Web
hypertension in pregnancy management guidelines 2024 2025
Reading File
Reading File
Reading Web Page
hypertension pregnancy management guidelines BP targets antihypertensives preeclampsia
Searching PubMed
"hypertensive disorders" AND "pregnancy" AND "management"
Reading File
I now have comprehensive information to compile a thorough answer. Let me synthesize everything.
Management of Hypertension in Pregnancy
Classification of Hypertensive Disorders of Pregnancy
| Category | Definition |
|---|---|
| Chronic hypertension | BP ≥140/90 mmHg diagnosed before pregnancy or before 20 weeks' gestation |
| Gestational hypertension | BP ≥140/90 mmHg new-onset after 20 weeks, without proteinuria or end-organ damage |
| Preeclampsia | Gestational hypertension + proteinuria (>300 mg/24 h) and/or end-organ damage (thrombocytopenia, renal insufficiency, elevated liver enzymes, pulmonary edema, neurological symptoms) |
| Eclampsia | Preeclampsia + seizures |
| Superimposed preeclampsia | Sudden BP worsening in previously controlled chronic hypertension, with new proteinuria or end-organ damage |
Persistent BP elevation beyond ~12 weeks postpartum after gestational hypertension or preeclampsia meets criteria for a new diagnosis of chronic hypertension. — Brenner and Rector's The Kidney
BP Targets: The Key Shift in 2025 Guidelines
The 2025 ACC/AHA Hypertension Guidelines (published August 2025) represent a major update from 2017, with new dedicated recommendations for pregnancy based primarily on the CHAP trial (Chronic Hypertension and Pregnancy):
| Setting | Target |
|---|---|
| Chronic hypertension in pregnancy | <140/90 mmHg (replaces older threshold of <160/105) |
| Severe hypertension (acute, any cause) | <160/110 mmHg (treat urgently) |
| Pre-pregnancy or planning pregnancy | <140/90 mmHg reasonable; insufficient data for stricter <130/80 target |
The CHAP trial showed that treating mild chronic hypertension to <140/90 mmHg significantly improved composite maternal and fetal outcomes without compromising fetal growth, overturning prior concerns about uteroplacental hypoperfusion. The earlier CHIPS trial also supported "tight" BP control (DBP target 85 mmHg) with reduced maternal complications (severe hypertension, thrombocytopenia, transaminitis) and no increase in pregnancy loss or high-level neonatal care.
Antihypertensive Drug Therapy
Chronic/Outpatient Management (First-Line Preferred Agents)
| Drug | Dose | Notes |
|---|---|---|
| Labetalol | 100 mg BD (oral) | α₁ + non-selective β blocker; preferred in 2025 ACC/AHA guidelines |
| Nifedipine extended-release | 30 mg OD | Ca²⁺ channel blocker; preferred in 2025 guidelines |
| Methyldopa | 250 mg BD | α₂ agonist; long safety record; rarely used outside pregnancy |
Acute/Inpatient Management (Severe Hypertension ≥160/110 mmHg)
| Drug | Dose | Route |
|---|---|---|
| Labetalol | 20 mg IV, escalate to 40–80 mg at 10-min intervals | IV |
| Hydralazine | 5–10 mg IV or IM every 20 min | IV/IM |
| Nifedipine | 10–20 mg oral, repeat at 20–30 min | Oral |
| Nicardipine | IV infusion (specialist use) | IV |
Severe hypertension (≥160/110 mmHg) requires treatment within 30–60 minutes to prevent maternal stroke and placental abruption.
Drugs to Avoid in Pregnancy
The 2025 ACC/AHA guidelines expanded the contraindication list:
- ACE inhibitors — fetotoxic (renal agenesis, oligohydramnios, skull defects)
- ARBs / Angiotensin receptor blockers — same fetal renal toxicity (newly added explicitly)
- Nitroprusside — fetal cyanide toxicity (newly added)
- Mineralocorticoid receptor antagonists (spironolactone, eplerenone generally) — antiandrogenic risk to male fetus; though eplerenone has been used where essential
- Atenolol — associated with fetal growth restriction
Preeclampsia Prevention
- Low-dose aspirin (81 mg/day) is recommended for all at-risk women (those with chronic hypertension, prior preeclampsia, diabetes, CKD, multifetal gestation, or multiple risk factors)
- Start between 12 and 28 weeks of gestation (ideally before 16 weeks) — NOT at conception
- This is a Class I recommendation (LOE B-R) in the 2025 ACC/AHA guidelines
Preeclampsia with Severe Features: Inpatient Management
- Antihypertensive therapy to reduce BP <160/110 mmHg acutely (drugs as above)
- Magnesium sulfate for seizure prophylaxis (eclampsia prevention) — especially when CNS symptoms present (headache, visual disturbance, altered mental status); also effective postpartum (up to ~48 h after delivery, as ~20% of eclampsia occurs postpartum)
- Delivery is definitive treatment — timing depends on gestational age:
- ≥37 weeks: prompt delivery
- 34–37 weeks with severe features: delivery usually recommended
- <34 weeks: expectant management in stable cases to allow corticosteroids for fetal lung maturation
Secondary Hypertension in Pregnancy
Secondary causes are present in ≥10% of women with chronic hypertension in pregnancy and carry higher complication rates:
- Renal artery stenosis (fibromuscular dysplasia) — diagnose with MR angiography; angioplasty/stenting described in 2nd/3rd trimester
- Pheochromocytoma — can be lethal if first detected at delivery; screen early, manage medically antepartum
- Primary hyperaldosteronism — may worsen in pregnancy despite progesterone's aldosterone-antagonizing effect; spironolactone used with caution (antiandrogenic risk)
- OSA — present in 40% of hypertensive pregnant women; screen in obese/snoring patients
Screening is hampered in pregnancy (ARR not validated; radiation-based imaging relatively contraindicated).
Postpartum Management
- Check BP 3–10 days after delivery in women with hypertensive disorders of pregnancy (ACOG recommendation)
- If BP normalizes and medications withdrawn: re-check at least annually
- History of preeclampsia/gestational hypertension = significant long-term risk factor for recurrent preeclampsia and cardiovascular disease — document and monitor indefinitely
- Women planning future pregnancy after prior preeclampsia: counsel on aspirin and optimize BP (extended-release nifedipine preferred as it is safe while breastfeeding; avoid ACE inhibitors/ARBs)
Pre-Conception Counseling
- Switch antihypertensives to pregnancy-safe agents before conception
- If pregnancy is unplanned, stop ACE inhibitors/ARBs immediately after confirmation
- Counsel on risks: superimposed preeclampsia, preterm birth, IUGR, abruption
- Target BP <140/90 mmHg pre-pregnancy (stricter <130/80 not yet evidence-based in this context)
Sources
- 2025 ACC/AHA Hypertension Guidelines (published Aug 2025) — AHA case applications incorporating CHAP trial data
- Brenner and Rector's The Kidney, 2-Volume Set — Chapters on Management of Hypertension in Pregnancy
- Goodman & Gilman's The Pharmacological Basis of Therapeutics — Pregnancy-Induced Hypertension/Preeclampsia
- CHAP Trial (key evidence base for the 2025 BP target shift)
- CHIPS Trial (tight vs. less-tight BP control)
This is a shared conversation. Sign in to Orris to start your own chat.